An mRNA-based flu vaccine (mRNA-1010) demonstrated 26.6% relative superiority over standard-dose licensed vaccines in preventing confirmed influenza illness in adults 50 and older , though the absolute difference was modest (2.0% vs. 2.8% infection rate). Solicited side effects were notably more common with the mRNA version, particularly injection-site pain and fatigue.
Seasonal influenza remains a significant public health burden in older adults, with current vaccines providing imperfect protection. This phase 3 randomized controlled trial tested whether an investigational mRNA vaccine encoding hemagglutinin proteins from WHO-recommended flu strains could improve on existing options.
Researchers enrolled 40,703 adults aged 50 and older across multiple sites. Half received the experimental trivalent mRNA-1010 vaccine (37.5 micrograms total), while the other half received a standard-dose licensed flu vaccine. The primary outcome was RT-PCR-confirmed influenza-like illness meeting protocol-defined criteria, tracked from at least 14 days post-vaccination through the end of the influenza season (median follow-up: 181 days).
The efficacy difference was statistically significant. Confirmed influenza illness occurred in 2.0% of mRNA-1010 recipients (411 of 20,179) compared to 2.8% of standard-vaccine recipients (557 of 20,124). This translates to 26.6% relative vaccine efficacy (95% CI, 16.7 to 35.4). The trial met its hierarchical testing criteria: it demonstrated noninferiority (the lower confidence boundary exceeded -10%), superiority (exceeded 0%), and higher-level superiority (exceeded 9.1%). In absolute terms, this means preventing approximately 8 additional cases per 1,000 vaccinated individuals.
The safety profile differed substantially between groups. Solicited local and systemic adverse reactions were more frequent with mRNA-1010: injection-site pain occurred in 65.8% versus 29.8%, fatigue in 45.1% versus 20.3%, headache in 37.8% versus 18.0%, and myalgia in 35.4% versus 11.6%. The majority of these reactions were mild to moderate and resolved within a few days. Serious adverse events were rare in both groups (2.2% with mRNA-1010 vs. 1.9% with standard vaccine), with only three events in the mRNA group and two in the control group attributed to vaccination by investigators.
This finding represents incremental progress in flu vaccine technology, not a transformative breakthrough. A 26.6% relative improvement translates to meaningful but not dramatic absolute protection gains. For adults 50 and older, the data suggest mRNA-1010 offers better odds of avoiding confirmed influenza infection compared to standard shots, though most vaccinated individuals in both groups remained infection-free.
The trade-off is genuine: expect more frequent and more intense short-term side effects if you receive the mRNA vaccine. The injection-site pain and fatigue rates are substantially higher, though transient. This is a practical consideration for people with low symptom tolerance or whose work schedules cannot accommodate a day of mild fatigue.
The study does not address whether this efficacy advantage persists in subsequent years, how it compares across different circulating influenza strains that emerge mid-season, or outcomes in adults younger than 50. These remain open questions. Additionally, the trial measured laboratory-confirmed illness, not hospitalizations or deaths, which are the outcomes that matter most clinically in older populations.
For individuals in this age group who develop severe complications from influenza, the modest protection gain may justify accepting the higher side-effect burden. For those at lower personal risk or with limited history of severe flu outcomes, the cost-benefit calculation may favor simpler tolerance of standard vaccines.
| Parameter | Value |
|---|---|
| Study Type | Phase 3, double-blind, randomized controlled trial |
| Sample Size | 40,703 adults (20,350 mRNA-1010; 20,353 standard vaccine) |
| Population | Adults aged 50 years and older |
| Intervention | mRNA-1010 (trivalent, 37.5 mcg total) vs. standard-dose licensed flu vaccine |
| Primary Outcome | RT-PCR-confirmed influenza-like illness (14+ days post-vaccination through season end) |
| Median Follow-up | 181 days (range 1-227 days) |
| Efficacy Result | 26.6% relative vaccine efficacy (95% CI, 16.7-35.4%) |
| Infection Rate, mRNA-1010 | 2.0% (411/20,179) |
| Infection Rate, Standard | 2.8% (557/20,124) |
| Most Common AE, mRNA-1010 | Injection-site pain (65.8%), fatigue (45.1%) |
| Most Common AE, Standard | Injection-site pain (29.8%), fatigue (20.3%) |
| Serious AE Rate | 2.2% mRNA-1010 (3 vaccine-related); 1.9% standard (2 vaccine-related) |
Efficacy and Safety of an mRNA Seasonal Influenza Vaccine in Adults - NEJM (PubMed: 42090792)
ProtocolEngine provides general health information based on published research. This is not medical advice. Consult a healthcare professional before starting any supplement or health protocol.
| The New England Journal of Medicine |
| Funding | Blackstone Life Sciences, Moderna |
| ClinicalTrials.gov | NCT06602024 |